Jeff Siegel is a Cap Specialist at Klutch Sports. He covers a diverse range of topics including finance, energy policy, cannabis business, and healthcare technology, with a particular focus on renewable energy and psychedelic research. Jeff's work has been featured in notable publications such as Psychology Today, Dallas Observer, Slate Magazine, and The Motley Fool.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jeff Siegel's coverage is diverse, with a focus on energy, sports, and finance & economy. His articles often cite data and involve investment analysis. This indicates that he may be interested in receiving pitches related to these themes.
When pitching Jeff Siegel, consider offering insights into the oil market, renewable energy investments or developments, as well as trends within horse racing. Additionally, providing data-backed investment analyses related to these topics could be particularly appealing to him based on his coverage attributes.
It's also important to note that while Jeff does not have a specific geographic focus mentioned, his interest in wine industry-related content isn't evident from the provided article titles; therefore it might not align with his current areas of interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Key Points Centrus dominates America's emerging HALEU fuel market. Record backlog provides years of revenue visibility.
Cash is plentiful, but execution remains critical. Lucid Group LCID reports second-quarter earnings on Aug. 4.
By: Jeff Siegel
AI demand could drive years of regulated earnings growth. Electric utilities don't typically raise long-term demand forecasts by one-third unless something meaningful has changed.
By: Jeff Siegel
Retailers could receive an unexpected financial windfall. Earlier this year, the Supreme Court ruled that President Donald Trump's broad
By: Jeff Siegel
BridgeBio Pharma BBIO has already been one of biotech's biggest winners over the past two years (up 209% as of July 31). Yet Barclays analyst Eliana Merle believes the rally may not be over.
By: Jeff Siegel
Key Points Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year.
The cannabis industry has taught investors a painful lesson over the past five years: Revenue growth means very little if a company can't generate cash.
Key Points Green Thumb continues generating profits while many rivals struggle. Strong cash flow supports disciplined share repurchases.
By: Jeff Siegel
Execution matters more than one disappointing quarter. The latest earnings report from Tesla TSLA wasn't pretty.
By: Jeff Siegel
Key Points Weak automotive margins continue pressuring near-term profitability. Robotaxis and Optimus remain the core investment thesis.
